Researchers at the University of Pretoria (UP) have been working to identify genes that make African women more susceptible to certain forms of breast cancer. However, this is no easy task as very little genomic information is known about African populations.

Breast cancer is the most prevalent cancer among women globally. According to the World Health Organisation, there were more than 2.26 million new cases of breast cancer in women in 2020, with a mortality rate of 685 000 women globally. It is estimated that a woman is diagnosed with breast cancer every 14 seconds somewhere in the world.

Since the end of 2020, about 7.8 million women have been living with breast cancer. In South Africa, it is predicted that about one in 27 women will develop breast cancer in their lifetime.

Cancer is caused by mutations in the genome. Many gene mutations may occur during a person’s life and are therefore not inherited. The latter may be triggered by risk factors such as acute or chronic stress, carcinogens, alcohol consumption, tobacco products, diet, lack of physical activity, environmental pollutants, ultraviolet radiation, reproductive and hormonal factors, occupational exposures, infection-attributable cancers, number of pregnancies, and age.

Developing breast cancer can also be an inherited genetic risk. About 5% to 10% of breast cancer cases are thought to be hereditary. Specific genetic variants (mutations) that women inherit from their parents may affect their probability of developing breast cancer. Having a first- or second-degree relative with breast cancer may double or triple the risk of being diagnosed with breast cancer.

Breast cancer susceptibility genes typically contain specific variants that decrease the ability of a woman’s body to repair damaged DNA. There are two types of variants that play a role in breast cancer. The first type is referred to as a germ line variant that is inherited. When specific germ line variants occur, the body is less likely to repair detrimental mutations that may cause cancer. The second type of variant is called a somatic variant and this takes place when DNA damage occurs during a woman’s lifetime, and is found in the DNA of cancerous cells.  

Germ line variants may increase a woman’s susceptibility to get breast cancer. While variants in several germ line breast cancer susceptibility genes play a role, the most-researched genes are involved in the repair of damaged DNA, and include BRCA1 and BRCA2, followed by PALB2. Examples of other important genes are ATM and TP53.

Detrimental variants in BRCA1 and BRCA2 are responsible for 5% to 10% of inherited breast cancer; however, many breast cancer patients have been shown not to have a BRCA1 or BRCA2 mutation. Having inherited specific mutations in BRCA1 or BRCA2 (or both) may increase a woman’s risk to up to 72% of developing breast cancer during her lifetime. PALB2 interacts with BRCA2 in DNA repair processes. Literature has shown that women with mutations in PALB2 may experience a 35% likelihood of developing breast cancer by the age of 70. 

They way in which breast cancer is diagnosed has developed significantly over the past few years. Breast cancer is classified as Luminal A, Luminal B, HER2+, triple negative, Claudin-low and Normal-like. In terms of common markers, testing is done for the presence of the progesterone receptor (PR), oestrogen receptor (ER) and for human epidermal growth factor receptor 2 (HER2) status. The presence of ER and PR implies that they can be treated with receptor-targeted treatment methods, where high HER2 levels typically indicate fast cancer growth, but may be targeted with drugs aimed at HER2.

Cancers without ER and PR and having low HER2 levels are termed triple-negative and are typically more challenging to treat, and require chemotherapy. The type of breast cancer as described above will assist in determining the path to follow in terms of ER-, PR- and HER2-targeted treatments, and the need for precision targeted-therapy, surgery, chemotherapy and radiation. Therefore, unlike many years ago, there is no blanket treatment for breast cancer, but it is individualised according to the type of cancer and the presence of specific gene variants.

An important factor is that most studies to design breast cancer susceptibility tests have been conducted on European and Asian populations, and breast cancer tests have been mainly designed from the latter data.

Only a small number of gene panel tests have been performed for African populations, with Nigerian patients and with patients from Uganda and Cameroon. Recent studies conducted by UP researchers Dewald Eygelaar, Lizette Janse van Rensburg and Fourie Joubert in 2022 investigated 165 South African breast cancer patients from various ethnolinguistic groups and indicated 9% of women with a family history of breast cancer (higher than the other two studies mentioned above). The UP team identified pathogenic/likely pathogenic variants in 13 patients in 10 different genes including BRCA1, BRCA2, PALB2 and others.

Larger-scale cancer susceptibility gene studies are crucial in South Africa and the rest of Africa, and future research should include large whole exome (the protein-coding part of the genome) or genome sequencing studies.

Recently, human genome sequencing has become much more affordable and several studies are taking place in Africa and specifically South Africa. This will inform researchers about the frequency of not only breast cancer susceptibility variants in Africans, but also about variants that influence a wealth of other inheritable conditions.

The complete strategy for the elimination of cancer requires a combination of awareness to address the burden of this disease, prevention strategies, contributing to early detection, promoting health and well-being education, together with the acceleration of science and discovery and progress in technology.

“We do what we do every day because we want to make a difference in someone's life,” Professor Annie Joubert says. “Our life’s journey has been shaped by people suffering from cancer and by family, friends, colleagues, peers, our executive and students, as well as indirectly by every individual who has crossed their paths.”

Early warning signs of breast cancer

According to the American Cancer Society, the most common symptom of breast cancer is a new lump or mass (although most breast lumps are not cancer). A painless hard mass that has irregular edges is more likely to be cancer, but breast cancers can also be soft, round, tender or even painful. These are few things to look out for:

• Swelling of all or part of a breast (even if no lump is felt)

• Skin dimpling (sometimes looks like an orange peel)

• Breast or nipple pain

• Nipple retraction (turning inward)

• Nipple or breast skin that is red, dry, flaking or thickened

• Nipple discharge (other than breast milk)

• Swollen lymph nodes under the arm or near the collar bone 

Click on the infographic in the sidebar to learn more.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam in vehicula elit. Cras mauris enim, gravida in erat sit amet, iaculis bibendum leo. Quisque vulputate sem nulla, at varius magna pulvinar mattis. Donec sodales imperdiet porttitor. Nullam posuere, enim ut fermentum ultrices, tortor velit elementum felis, a feugiat nisl lorem sed nisi. Morbi eleifend, quam eu dictum lacinia, eros mauris euismod lectus, et rhoncus orci risus at tellus. Praesent hendrerit sit amet sapien vitae posuere.

Quisque nec mi dolor. Ut rhoncus tortor iaculis, scelerisque erat sit amet, pellentesque nisi. Cras dignissim, ipsum nec imperdiet posuere, magna lorem rhoncus purus, vel ullamcorper velit nunc vitae dolor. Duis ut convallis nulla, nec gravida orci. Pellentesque vehicula sed massa vitae tempus. Aenean ut auctor ex, ut pulvinar justo. Integer ullamcorper, nunc at eleifend lobortis, mi quam tincidunt lorem, eget posuere neque mi pulvinar dui. Sed sed libero venenatis, maximus tellus at, posuere quam. Etiam tempor quam quis congue vehicula. Cras condimentum vel metus ut iaculis. Nullam pretium euismod urna. Fusce magna augue, feugiat sed velit quis, condimentum aliquet nisl.

Suspendisse sagittis sem vitae metus viverra, sit amet semper lacus rhoncus. Interdum et malesuada fames ac ante ipsum primis in faucibus. Donec in metus erat. Suspendisse ut nulla a eros dapibus aliquet nec vel elit. Cras non pharetra ex, quis sagittis mauris. Aenean cursus nulla odio, nec dignissim mi tincidunt nec. Phasellus luctus iaculis magna vitae finibus. Morbi interdum lacus non convallis imperdiet. Cras volutpat nec erat ut viverra. Nulla vulputate risus tortor, non tristique justo tempus id.

Suspendisse tempus orci ipsum. Curabitur consectetur at elit nec consectetur. Fusce pretium vulputate odio in maximus. Praesent ultricies lorem eu facilisis tincidunt. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque mollis malesuada velit rutrum bibendum. Morbi sed turpis nec metus tempus consectetur eget non diam. Morbi hendrerit ullamcorper magna id rhoncus. Aliquam erat volutpat. Pellentesque tincidunt eget mi at finibus. Phasellus maximus eros a fermentum vulputate. Suspendisse posuere purus vel tincidunt hendrerit. Vivamus a sem at nibh ullamcorper feugiat quis et ipsum.

Fusce convallis interdum erat ullamcorper accumsan. Proin lacinia justo ut odio imperdiet placerat. Sed varius risus eget aliquam blandit. Sed condimentum quam augue, in mollis quam rhoncus non. Etiam elementum semper condimentum. Sed dignissim sem vitae ante egestas blandit. Cras eros metus, volutpat eget suscipit quis, tincidunt vitae dui. Pellentesque laoreet arcu odio, eget bibendum purus hendrerit in. Donec rhoncus enim nisl, eu commodo arcu mollis id. Morbi porttitor pharetra felis a fringilla. Nam suscipit turpis ut nulla luctus, ultrices euismod turpis bibendum. Cras tristique facilisis ante, in interdum nulla varius non. In tincidunt dui efficitur lorem pellentesque commodo. Vestibulum imperdiet eu eros eu finibus.